• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Psoriasis, Seborrhea and Ichthyosis
    29 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Abitrexate
    Salomon, Levin & Elstein Ltd
    RX
    partial basket chart
    Abitrexate

    Folic Acid Analog. Methotrexate 25 mg/ml.
    VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
    8 ml, 20 ml, 40 ml. Dose must be ajust.
    individ. for each pt. accord. to med.
    cond. See lit.
    Antineopl. Chemother.
    Tmt. of gestational choriocarcinoma,
    chorioadenoma destruens and
    hydatidiform mole. Palliation of ALL. Tmt.
    and proph. of menin. leukemia.
    Greatest effect has been observed in
    palliation of acute lymphoblast.(stemcell)
    leukemias in child. In comb. with
    other anticancer agents, may be used for
    the induc. of remis.,but is most common.
    used in the mainten. of induced remis.
    May be used alone, or in comb. with other
    antineoplastic drugs, in the manag. of
    breast canc., epidermoid cancers of the
    head and neck, lung cancer (partic.
    squamous cell ,small cell types), bladder
    cancer and osteogenic cancer. Tmt. of the
    advan.stages (III and IV, Peter’s Staging
    system) of lymphosarcoma, partic. in
    child., and in advanced cases of mycosis
    fungoides.
    Psoriasis. Indic. only in the sympt. control
    of sev. recalcitrant, disabling psoriasis
    which is not adeq. responsive to other
    forms of therapy, and only when the diag.
    has been established, as by biopsy and/or
    after dermat. consult. RA:Tmt. of selec.
    adul.with sev. RA, only when the diag. has
    been well established accord. to rheumat.
    standards, with inadeq. response to other
    forms of antirheum. ther., includ. full dose
    NSAIDs and usually a trial of at least one
    or more dis.-modif. antirheum. drugs.
    C/I: Pregnancy, lact., pts. in poor state of
    nutrition, sev. ren. impair. (crCL <20 ml/
    min), sev. liver impair., bone marrow
    hypoplasia, leucopenia,
    thrombocytopenia, anemia, alcohol
    abuse, hypersens. and lung toxic.due to
    methotrexate, serious, acute or chronic
    infect. such as tuberculosis and HIV,
    ulcers of the oral cavity and known
    active GI ulcer dis. Concur. vaccin. with
    live vaccines.

    Alphosyl “2 In 1” Shampoo with Conditioner
    Perrigo
    OTC
    not in the basket chart
    Alphosyl “2 In 1” Shampoo with Conditioner

    Coal Tar 5% w/w.
    SHAMPOO WITH CONDITIONER: 250 ml.
    Use 2-3 x wkly.
    Scaling and relief itch. scalp disords. of
    dandruff, psoriasis, seborrh., ecz.
    C/I: Sensitiv., skin infect.

    Balneum Hermal Plus
    Neopharm
    OTC
    not in the basket chart
    Multiple ingredients
    Balneum Hermal Plus

    Polidocanol 15 g / 100 g, Soya Oil 82.95 g / 100 g.
    LIQ: 200 ml, 500 ml. Shake before use.
    For bath or shower.
    Medicinal oil bath with antiprurit. effect,
    skin dis.

    Capasal Therapeutic Shampoo
    Trupharm
    OTC
    not in the basket chart
    Multiple ingredients
    Capasal Therapeutic Shampoo

    Salicylic Acid 0.5%, Coal Tar 1%, Coconut Oil 1%.
    SHAMPOO: Bottle: 250 ml.
    Use as shampoo dly. if necess. See
    package.
    Dandruff, seborrh. ecz., seborrh. dermatit,
    psoriasis, cradle cap in child.

    Cetrimide Shampoo Vitamed
    Vitamed
    OTC
    full basket chart
    Cetrimide Shampoo Vitamed

    Cetrimide 10% w/v.
    SHAMPOO: 100 ml. Use as reg. shampoo
    but not with soap or other shampoo.
    Dandruff.
    C/I: Inf. under 1 yr.

    Cosentyx 150 mg
    Novartis
    RX
    partial basket chart
    Cosentyx 150 mg

    Interleukin Inhibitor. Secukinumab 150 mg.
    VIAL(pwdr. for sol. for inj.): 1×6ml.
    PRE FILL. PEN/SYR (sol. for inj.): 1, 2×1ml Plaque psorias.: 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg. Psoriat. arthrit.: For pts. with concom. moder.-sev. plaque psorias. or who are anti-TNFα inadeq. responders (IR): 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg.
    For other pts.: dose is 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by monthly mainten. dosing. Ankylos. spondylit.: 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing.
    For all of the above indications, usually achieved within 16 wks. of tmt. Consider. should be given to discont. tmt. in pts. who have shown no response by 16 wks. of tmt. Some pts. with an init. partial response may subseq. improve with continued tmt. beyond 16 wks.
    Plaque psorias.: Tmt. of moder.- sev. plaque psorias. in adult. who are candidates for system. ther.
    Psoriat. arthrit.: Alone or in comb. with methotrexate (MTX): tmt. of active psoriat. arthrit. in adult pts. when the response to previous dis.-modif. anti-rheumatic drug (DMARD) ther. has been inadeq.
    Ankylosing spondylitis: Tmt. of active ankylos. spondylitis in adult. who have responded inadeq. to convent. ther.
    C/I: Severe hypersens. Clinical. important, active infec. (e.g. active tuberculosis).


    Other therapeutic systems under Dermatological Preparations

    CLOSE